Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Macrogenics's Other Operating Expense for the
three
months ended in Mar. 2026 was €0.0 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.0 Mil.
Macrogenics's quarterly Other Operating Expense
declined
from Sep. 2025 (€0.0 Mil) to Dec. 2025 (€-0.0 Mil) but then
increased
from Dec. 2025 (€-0.0 Mil) to Mar. 2026 (€0.0 Mil).
Macrogenics's annual Other Operating Expense
increased
from Dec. 2023 (€-0.0 Mil) to Dec. 2024 (€0.0 Mil) but then
declined
from Dec. 2024 (€0.0 Mil) to Dec. 2025 (€-0.0 Mil).
Macrogenics Other Operating Expense Related Terms
Macrogenics Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Macrogenics's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of €-0.0 Mil mean?
Macrogenics (FRA:M55) has a Other Operating Expense of €-0.0 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Macrogenics and its competitors.
Is Macrogenics' Other Operating Expense too high?
Macrogenics' current Other Operating Expense is €-0.0 Mil. Overall, Macrogenics has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' Other Operating Expense compare to RNAC and CNXU?
Macrogenics' Other Operating Expense of €-0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Macrogenics and its competitors. Macrogenics's current Other Operating Expense is €-0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Based on GuruFocus' analysis, Macrogenics (FRA:M55) is currently considered Fairly Valued. The stock's GF Value™ is €3.67, compared to a current price of €3.46 — trading 5.7% below its estimated fair value. The current Other Operating Expense is €-0.0 Mil. Macrogenics' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Macrogenics (FRA:M55), the current Other Operating Expense is €-0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Macrogenics (FRA:M55) Overvalued in 2026?
Based on GuruFocus' analysis, Macrogenics stock appears to be undervalued.
The current stock price of €3.46 is trading 5.7% below its estimated GF Value™ of €3.67.
GuruFocus considers Macrogenics to be Fairly Valued.
Key valuation signals for FRA:M55:
Other Operating Expense: €-0.0 Mil
GF Value™: €3.67 vs. price of €3.46 (5.7% below fair value)
No single metric tells the full story. See the FRA:M55 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
54GF Score
Get the complete analysis for FRA:M55
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M55 has been successfully added to your 
